Cimlanod
Jump to navigation
Jump to search
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
Chemical and physical data | |
Formula | C5H7NO4S |
Molar mass | 177.17 g·mol−1 |
3D model (JSmol) | |
|
Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a precursor of nitroxyl.[1]
Cimlanod is a prodrug of CXL-1020.[2]
A preliminary study showed efficacy in patients with class III and IV heart failure.[3] A phase II clinical trial was completed in 2016.[4]
References
- ^ "BMS 986231". AdisInsight. Springer Nature Switzerland AG. Retrieved 2017-05-22.
Alternative Names: BMS-986231; CXL 1427; HNO Donor
- ^ "CXL 1020". AdisInsight. Springer Nature Switzerland AG. Retrieved 2017-05-22.
- ^ Zoler ML (22 May 2016). "Nitroxyl prodrug shows promise in acute heart failure".
- ^ Clinical trial number NCT02157506 for "A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure" at ClinicalTrials.gov
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Experimental drugs
- Furans
- Sulfonamides
- All stub articles
- Cardiovascular system drug stubs